Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck

Wagenblast,Jens; Hirth,Daniel; Thron,Laura; Arnoldner,Christoph; Diensthuber,Marc; Stöver,Timo; Hambek,Markus

doi:10.3892/ol.2012.700

Effects of the Polo-like-kinase-1-inhibitor BI2536 in squamous cell carcinoma cell lines of the head and neck

Authors:
- Jens Wagenblast
- Daniel Hirth
- Laura Thron
- Christoph Arnoldner
- Marc Diensthuber
- Timo Stöver
- Markus Hambek
View Affiliations

Affiliations: ENT Department, Medical School, Goethe University, D-60590 Frankfurt am Main, Germany, ENT Department, Medical University of Vienna, A-1090 Vienna, Austria
Published online on: April 30, 2012 https://doi.org/10.3892/ol.2012.700
Pages: 175-177

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inhibition of the Polo-like-kinase-1 (PLK1) has been shown to be effective in a number of solid tumor models. In this in vitro study, we examined the antitumor effect of BI2536, a small molecule inhibitor of PLK1, in squamous cell carcinoma of the head and neck (SCCHN) cell lines. Dose escalation studies were performed with nine SCCHN cell lines using BI2536. Growth inhibitory and proapoptotic effects were measured quantitatively using cytohistology and a Human Apoptosis Array Kit. BI2536 demonstrated a significant antiproliferative and apoptotic activity in all nine SCCHN cell lines investigated (p<0.009). Our results indicate that inhibition of PLK1 by BI2536 leads to an antiproliferative and apoptotic effect in SCCHN cell lines. In vivo and in the clinical setting, the application of BI2536 may support the antitumoral activity of conventional drugs that are in current use and could decrease the systemic toxicity of these drugs.

View Figures

View References

1	Mehanna H, Paleri V, West CM and Nutting C: Head and neck cancer - Part 1: epidemiology, presentation, and prevention. BMJ. 341:c46842010. View Article : Google Scholar : PubMed/NCBI
2	Maden C, Beckmann AM, Thomas DB, McKnight B, Sherman KJ, Ashley RL, et al: Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. Am J Epidemiol. 135:1093–1102. 1992.PubMed/NCBI
3	Wagenblast J, Hambek M, Baghi M, Gstottner W, Strebhardt K, Ackermann H, et al: Antiproliferative activity of bortezomib alone and in combination with cisplatin or docetaxel in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol. 134:323–330. 2008. View Article : Google Scholar : PubMed/NCBI
4	Renner AG, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A, et al: Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood. 114:659–662. 2009. View Article : Google Scholar : PubMed/NCBI
5	Van de Weerdt BC and Medema RH: Polo-like kinases: a team in control of the division. Cell Cycle. 5:853–864. 2006.PubMed/NCBI
6	Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al: BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 17:316–322. 2007. View Article : Google Scholar : PubMed/NCBI
7	Takai N, Hamanaka R, Yoshimatsu J and Miyakawa I: Polo-like kinases (Plks) and cancer. Oncogene. 24:287–291. 2005. View Article : Google Scholar : PubMed/NCBI
8	Strebhardt K and Ullrich A: Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 6:321–330. 2006. View Article : Google Scholar : PubMed/NCBI
9	Datta D, Banerjee P, Gasser M, Waaga-Gasser AM and Pal S: CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1. J Biol Chem. 285:36842–36848. 2010. View Article : Google Scholar : PubMed/NCBI
10	Ray RB, Raychoudhuri A, Steele R and Nerurkar P: Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis. Cancer Res. 70:1925–1931. 2010.PubMed/NCBI
11	Holtrich U, Wolf G, Brauninger A, Karn T, Bohme B, Rubsamen-Waigmann H, et al: Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci USA. 91:1736–1740. 1994. View Article : Google Scholar : PubMed/NCBI
12	Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, et al: Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene. 14:543–549. 1997. View Article : Google Scholar : PubMed/NCBI
13	Knecht R, Elez R, Oechler M, Solbach C, von Ilberg C and Strebhardt K: Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 59:2794–2797. 1999.PubMed/NCBI
14	Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al: Cancer statistics. CA Cancer J Clin. 55:10–30. 2005.
15	Wagenblast J, Baghi M, Arnoldner C, Bisdas S, Gstottner W, Ackermann H, et al: Cetuximab enhances the efficacy of bortezomib in squamous cell carcinoma cell lines. J Cancer Res Clin Oncol. 135:387–393. 2009. View Article : Google Scholar : PubMed/NCBI
16	Schoffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, et al: Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer. 46:2206–2215. 2010.